PHILADELPHIA — Two specific genetic variations in people of African descent are responsible for persistent atopic dermatitis (AD), an itchy, inflammatory form of the skin disorder eczema. A new report by researchers in the Perelman School of Medicine at the University of Pennsylvania found that loss-of-function mutations to Filaggrin-2 (FLG2), a gene that creates a protein responsible for retaining moisture and protecting the skin from environmental irritants, were associated with atopic dermatitis in African American children. The study, the first report to deduce the mechanism responsible for the persistent form of the condition in African American children, was published in the Journal of Allergy and Clinical Immunology.
Nearly half of people with atopic dermatitis in the United States are African-American children. Previous studies have shown than those of African descent do not usually carry a mutation to the filaggrin gene (FLG) that has been associated with the risk of onset and persistence of AD in those of European and Asian ancestry.
"This finding helps confirm that skin barrier proteins are important in Atopic Dermatitis for people of all ancestries," said lead study author David Margolis, MD, PhD, professor of Dermatology and Epidemiology. "It could also lead to a way to determine which children are most likely to have persistent flare ups throughout their lives."
The team evaluated DNA from 299 African American children, none of whom had experienced skin free of symptoms of AD while not on medication in the previous 6 months. Within the group, researchers discovered that children with either one of two FLG2 mutations - rs12568784 or rs16833974 - were more than 50 percent more likely to have persistent AD than those without the mutations.
Future research will work to better understand mutations of FLG2 and determine if they result in functional changes to the FLG2 protein. In addition, the team is continuing research into mechanisms that may turn off the immune response to irritants that pass through the dysfunctional skin barrier and incite the inflammatory response seen in AD.
The Penn study team includes Jayanta Gupta, MD, PhD, Andrea Apter, MD, MSc, Tapan Ganguly, PhD, Ole Hoffstad, MA, Maryte Papadopoulos, MBE, Tim Rebbeck, PhD, and Nandita Mitra, PhD, from the departments of Biostatistics and Epidemilology, Dermatology, Medicine and the DNA Sequencing Facility.
The study was funded by the National Institute of Arthritis Musculoskeletal and Skin Diseases (NIAMS, R01-AR0056755) and a grant from Valeant Pharmaceuticals for the Pediatric Eczema Elective Registry study.
Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $4.3 billion enterprise.
The Perelman School of Medicine has been ranked among the top five medical schools in the United States for the past 16 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $398 million awarded in the 2012 fiscal year.
The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania -- recognized as one of the nation's top "Honor Roll" hospitals by U.S. News & World Report; Penn Presbyterian Medical Center; Chester County Hospital; Penn Wissahickon Hospice; and Pennsylvania Hospital -- the nation's first hospital, founded in 1751. Additional affiliated inpatient care facilities and services throughout the Philadelphia region include Chestnut Hill Hospital and Good Shepherd Penn Partners, a partnership between Good Shepherd Rehabilitation Network and Penn Medicine.
Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2012, Penn Medicine provided $827 million to benefit our community.
Department of Communications
For Patients and the General Public: